Skip to content

effect of midazolam- ketamine combination in refractory status epilepticus

Comparison of the efficacy of ketamine-midazolam combination with midazolam alone in the treatment of status epilepticus resistant to first- and second-line treatments in patients with refractory status epilepticus

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221022056269N1
Enrollment
20
Registered
2023-01-28
Start date
2022-11-24
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory status epilepticus. Other disorders of nervous system in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: The intervention group of ketamine drug, which is part of the category of anesthetic drugs, in the form of intravenous injection with a dose of 3 mg along with mida

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with refractory status epilepticus Age between 18-50 years ohd

Exclusion criteria

Exclusion criteria: The pregnant patients The patients with sepsis Post hypoxic patients The patients with multi organ damage The patients with high blood pressure and increased intracranial pressure

Design outcomes

Primary

MeasureTime frame
Level of consciousness, galasco coma score. Timepoint: The beginning of the study and one hour later and twenty four hours later. Method of measurement: glasco score coma.;Ststus seizure termination time. Timepoint: one houre later. Method of measurement: Based on the patient's clinical symptoms.

Secondary

MeasureTime frame
The secondary outcome variable is the examination of the amount of drug side effects in the two study groups, which is checked based on the patient's clinical symptoms. Timepoint: At the beginning of the study, the blood pressure and heart rate of the patients and the electrocardiogram of the patients are taken. Method of measurement: Use of sphygmomanometer and heart rate monitor.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Kiani ara

Shiraz University of Medical Sciences

fateme81kiani71@gmail.com+98 71 3647 4332

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026